Quantitative determination of rivaroxaban in pharmaceutical formulations by ultra performance liquid chromatography

Year 2024, Volume: 3 Issue: 3, 93 - 100, 31.12.2024

Murat Kozanlı , Nafiz Öncü Can

https://doi.org/10.55971/EJLS.1535613

https://izlik.org/JA32SX37CJ

Abstract

Rivaroxaban, which is a factor Xa inhibitor, effectively prevents clot formation in cardiovasculary system. In this study, a novel UPLC method was developed to provide an accurate, sensitive, fast, and reliable way for qualitative and quantitative analysis of rivaroxaban in pharmaceutical dosage forms. Chromatographic separation was achieved using a Phenomenex C18-bonded fused-core silica column (Kinetex® 2.6 μm, 150 mm × 3 mm i.d.). The separation was performed in isocratic mode with a mobile phase consisting of water, acetonitrile, and methanol (55:20:25, v/v/v), at a flow rate of 0.5 mL min-1, a column temperature of 40 °C, and a detection wavelength of 249 nm. The method was validated according to ICH Q2(R1) guideline for linearity, range, LOD and LOQ, accuracy, and precision and was successfully implemented to the analysis of rivaroxaban in tablet formulations.

Keywords

Rivaroxaban , Pharmaceutical formulation , UPLC

References

• Eswarudu M, Devi AL, Pallavi K, Babu PS, Priya SN, Sulthana SHS. Novel validated RPHPLC method for determination of rivaroxaban in bulk and its pharmaceutical dosage form. Int J Pharm Sci Rev Res. (2020);64(1):183-187. https://doi.org/10.47583/ijpsrr.2020.v64i01.033
• Çelebier M, Reçber T, Koçak E, Altinöz S. RP-HPLC method development and validation for estimation of rivaroxaban in pharmaceutical dosage forms. Braz J Pharm Sci. (2013); 49:359-366. https://doi.org/10.1590/S198482502013000200018
• Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. (2011);10(1):61-75. https://doi.org/10.1038/nrd3185
• Vanassche T, Vandenbriele C, Peerlinck K, Verhamme P. Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. Expert Opin Pharmacother. (2015);16(5):645-658. https://doi.org/10.1517/14656566.2015.999043
• Reçber T, Haznedaroğlu İC, Çelebier M. Review on characteristics and analytical methods of rivaroxaban. Crit Rev Anal Chem. (2022);52(4):865-877. https://doi.org/10.1080/10408347.2020.1839735
• Samama MM. The mechanism of action of rivaroxaban–an oral, direct Factor Xa inhibitor– compared with other anticoagulants. Thromb Res. (2011);127(6):497-504. https://doi.org/10.1016/j.thromres.2010.09.008
• Özcan S, Öğüt EG, Levent S, Can NÖ. A new HPLC method for selexipag analysis in pharmaceutical formulation and bulk form. Eur J Health Sci. (2023);2(2):53-58. https://doi.org/10.55971/EJLS.1320502
• Gumustas M, Kurbanoglu S, Uslu B, Ozkan SA. UPLC versus HPLC on drug analysis: advantageous, applications and their validation parameters. Chromatographia. (2013);76:1365-1427. https://doi.org/10.1007/s10337-013-2477-8
• Bhavyasri K, Dhanalakshmi C, Sumakanth M. Development and validation of ultra violetvisible spectrophotometric method for estimation of rivaroxaban in spiked human plasma. J Pharm Sci Res. (2020);12(9):1215-1219.
• Çelebier M, Kaynak M, Altınöz S, Şahin S. UV spectrophotometric method for determination of the dissolution profile of rivaroxaban. Dissolution Technol. (2014);21(4):56-59. https://doi.org/10.14227/DT210414P56
• Sekaran CB, Bind VH, Damayanthi MR, Sireesha A. Development and validation of UV spectrophotometric method for the determination of rivaroxaban. Der Pharma Chemica. (2013);5(4):1-5.
• Pinaz AK, Muralikrishna K. Area Under Curve Spectrophotometric Method for Determination of Rivaroxaban in Bulk and Tablet Formulation and Its Validation. Asian J Pharm Res. (2013);3(3):109-113.
• Seshamamba B, Sekaran C. Spectrophotometric quantification of direct factor xa inhibitor, rivaroxaban, in raw and tablet dosage form. Glob Drugs and Therap. (2017);2(3):1-8. https://doi.org/10.15761/GDT.1000122
• Seshamamba BSV, Sekaran CB. Spectrophotometric Analysis for the Quantification of Rivaroxaban in Bulk and Tablet Dosage Form. Int J Med Pharm Sci. (2017);7:21-34.
• El-Bagary RI, Elkady EF, Farid NA, Youssef NF. A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of Cilostazol and Rivaroxaban in Pharmaceutical Preparations Using Fe-Phenanthroline System. Anal Chem Lett. (2017);7(5):676-688. https://doi.org/10.1080/22297928.2017.1385420
• Sahoo S, Mekap SK. Assay comparison of rivaroxaban by new HPLC method with an existing method in tablet dosage form. Pharm Biol Eval. (2017);4:180-182. https://doi.org/10.26510/2394-0859.pbe.2017.27
• Nımje H, Chavan R, Pawar S, Deodhar M. Development and validation of stabilityindicating RP-HPLC method for rivaroxaban in tablet dosage form. J Res Pharm. (2022);26(6):1703-1712. https://doi.org/10.29228/jrp.261
• Kasad PA, Muralikrishna K. Design and validation of dissolution profile of rivaroxaban by using RP-HPLC method in dosage form. Asian J Pharm Anal. (2013);3(3):75-78.
• Pinaz AK, Muralikrishna K. Method development and acid degradation study of rivaroxaban by RP-HPLC in bulk. Asian J Pharm Anal. (2013);3(2):62-65.
• Lories I, Mostafa A, Girges M. High performance liquid chromatography, TLC densitometry, first derivative and first derivative ratio spectrophotometry for determination of rivaroxaban and its alkaline degradates in bulk powder and its tablets. J Chromatogr Sep Tech. (2013);4(8):1-6. https://doi.org/10.4172/2157-7064.1000202
• Seshamamba BSV, Satyanarayana PVV, Sekaran CB. Application of stability indicating HPLC method with UV detector to the analysis of rivaroxaban in bulk and tablet dosage form. Chem Sci Trans. (2014);3(4):1546-1554. https://doi.org/10.7598/cst2014.893
• Walter ME, Perobelli RF, Da Silva FS, Cardoso Junior C, da Silva IS, Dalmora SL. Development and validation of a stability-indicating RP-HPLC method for the determination of rivaroxaban in pharmaceutical formulations. Lat American J Pharm. (2015);34(8):1503-1510.
• Hadagali MD. Determination of rivaroxaban in pure, pharmaceutical formulations and human plasma samples by RP-HPLC. Int J Adv Pharm Anal. (2015);5(3):65-68. https://doi.org/10.7439/ijapa.v5i3.2800
• Souri E, Mottaghi S, Zargarpoor M, Ahmadkhaniha R, Jalalizadeh H. Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms. Acta Chromatogr. (2016);28(3):347-361. https://doi.org/10.1556/1326.2016.28.3.05
• Girase Y, Srinivasrao V, Soni D. Development and validation of stability-indicating RPHPLC method for rivaroxaban and its impurities. SOJ Biochem. (2018);4:1-6. https://doi.org/10.15226/2376-4589/4/1/00127
• Badroon T, Sreeramulu J. Development and validation of stability indicating assay by HPLC method for estimation of Rivaroxaban. Int J Bio-Pharm Res. (2019);8(5):2582-2586.
• Rajan N, Basha KA. A stability-indicating ultra-performance liquid chromatographic method for estimation of related substances and degradants in Rivaroxaban active pharmaceutical ingredient. J Pharm Res. (2014); 8(11):1719-1725.
• Rao P, Cholleti V, Reddy V. Stability-indicating UPLC method for determining related substances and degradants in Rivaroxaban. Int J Res Pharm Sci. (2015); 5(2):17-24.
• Vaghela D, Patel P. High performance thin layer chromatographic method with densitometry analysis for determination of rivaroxaban from its tablet dosage form. International Int J Pharm Pharm Sci. (2014);6(6):383-386.
• Alam P, Ezzeldin E, Iqbal M, Anwer MK, Mostafa GA, Alqarni MH, Foudah AI, Shakeel F. Ecofriendly densitometric RP-HPTLC method for determination of rivaroxaban in nanoparticle formulations using green solvents. RSC Advances. (2020);10(4):2133-2140. https://doi.org/10.1039/C9RA07825H
• Ramisetti NR, Kuntamukkala R. Development and validation of a stability indicating LCPDA-MS/MS method for separation, identification and characterization of process related and stress degradation products of rivaroxaban. RSC Advances. (2014);4(44):23155-23167. https://doi.org/10.1039/C4RA00744A
• Arous B, Al-Mardini MA, Ghazal H, Al-Lahham F. Stability-Indicating Method for the Determination of Rivaroxaban and its Degradation Products using LC-MS and TLC. Res J Pharm Technol. (2018);11(1):212-220. https://doi.org/10.5958/0974-360X.2018.00040.9
• Borman P, Elder D. Q2 (R1) validation of analytical procedures: text and methodology. ICH quality guidelines: an implementation guide; (2017).p.127-166. https://doi.org/10.1002/9781118971147.ch5